Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A RAPID PAN-VIRAL MICROARRAY DIAGNOSTIC FOR CATEGORY A-C BIODEFENSE PATHOGENS

Award Number: R56AI089532
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/09/2010
PERIOD OF PERFORMANCE END DATE: 06/30/2013

Group Awards By:

View Award Description

A RAPID PAN-VIRAL MICROARRAY DIAGNOSTIC FOR CATEGORY A-C BIODEFENSE PATHOGENS - ABSTRACT Rapid and accurate diagnosis of individuals exposed to and / or infected with NIAID Category A-C viral pathogens is critical because of the threat to national security and potential to spread and quickly disseminate in a vulnerable population. Currently available diagnostics are typically neither able to diagnose all known viral causes of outbreaks or bioterrorist threats in a single test, nor capable of identifying novel variants of known viruses. We have previously developed a DNA microarray (Virochip) as a broad-spectrum surveillance platform for detection of all known viruses. Since the Virochip does not rely on use of virus-specific priming, it is also well-suited for detection of novel viruses, and has been previously used to identify SARS coronavirus and 2009 novel H1N1 influenza A virus in the absence of a priori knowledge of the pathogen. In conjunction with Akonni Biosystems, we propose to develop and validate a Virochip-based diagnostic assay for Category A-C viral pathogens (Biothreat Detection Virochip) that is rapid (<2 hour turnaround time), sensitive / specific, portable, and cost-effective, yet capable of simultaneously detecting all Category A-C viruses as well as related novel variants. We will also develop and test a secondary Pan-Influenza Detection Virochip for rapid subtyping and characterization of novel influenza strains. We will rigorously assess the performance characteristics of these assays for detection of Category A-C viral pathogens using positive clinical specimens, cultured virus stocks, and cDNA plasmids / in vitro transcribed mRNA containing viral sequence. We will test viruses that are BSL-3/4 select biological agents using clinical specimens from infected humans as well as from non-human primates and rodents inoculated with live virus. Through an extensive network of worldwide collaborators in Canada, Mexico, the United States, India, and Africa, we will analyze surveillance and outbreak clinical specimens (n ~ 2,500) for Category A-C viral pathogens in cases of influenza-like illness, diarrhea, sepsis, and encephalitis. Our goal is a clinical sensitivity of >90% and specificity of >99% for detection of Category A-C viral pathogens relative to PCR methods and conventional laboratory testing, using direct viral sequence recovery as the gold standard for detection. We will analyze the remaining negative outbreak specimens by deep sequencing methods to discover novel viruses associated with outbreaks, and perform preliminary conventional and molecular epidemiology to assess whether these novel viruses are likely to be causal. This project is innovative because it translates a well-established pan-viral microarray platform that has the additional capacity to detect novel variants (Virochip) into a portable, sample-to-answer system (Akonni) for rapid detection of all Category A-C viruses. The significance of this research is that a rapid and comprehensive yet portable diagnostic assay for Category A-C viruses could be deployed in public health agencies, hospitals, and point-of-care sites to assist in outbreak and bioterrorist investigation. The use of panviral microarray and deep sequencing strategies will also facilitate efforts to discover novel viruses that may be previously unrecognized emerging pathogens or potential agents of bioterrorism.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $0 )
2013	2010	UNIVERSITY OF CALIFORNIA-SAN FRANCISCO	BOX 0812	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Trans-NIH Recovery Act Research Support	000	1	11/30/2012	NEW	$0
														Subtotal = $0

Issue Date FY: 2012 ( Subtotal = $0 )
2012	2010	UNIVERSITY OF CALIFORNIA-SAN FRANCISCO	BOX 0812	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Trans-NIH Recovery Act Research Support	000	1	10/26/2011	NEW	$0
														Subtotal = $0

Issue Date FY: 2010 ( Subtotal = $888,279 )
2010	2010	UNIVERSITY OF CALIFORNIA-SAN FRANCISCO	BOX 0812	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Trans-NIH Recovery Act Research Support	000	1	8/9/2010	NEW	$888,279
														Subtotal = $888,279

Grand Total All Awards = $888,279

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A RAPID PAN-VIRAL MICROARRAY DIAGNOSTIC FOR CATEGORY A-C BIODEFENSE PATHOGENS

Award Number: R56AI089532

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/09/2010

PERIOD OF PERFORMANCE END DATE: 06/30/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer